Dysarthria in individuals with Parkinson's disease: A protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark)

Serge Pinto, Rita Cardoso, Jasmin Sadat, Isabel Guimarães, Céline Mercier, Helena Santos, Cyril Atkinson-Clement, Joana Carvalho, Pauline Welby, Pedro Oliveira, Mariapaola D'Imperio, Sónia Frota, Alban Letanneux, Marina Vigario, Marisa Cruz, Isabel Pavão Martins, François Viallet, Joaquim J. Ferreira

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Individuals with Parkinson's disease (PD) have to deal with several aspects of voice and speech decline and thus alteration of communication ability during the course of the disease. Among these communication impairments, 3 major challenges include: (1) dysarthria, consisting of orofacial motor dysfunction and dysprosody, which is linked to the neurodegenerative processes; (2) effects of the pharmacological treatment, which vary according to the disease stage; and (3) particular speech modifications that may be language-specific, that is, dependent on the language spoken by the patients. The main objective of the FraLusoPark project is to provide a thorough evaluation of changes in PD speech as a result of pharmacological treatment and disease duration in 2 different languages (French vs European Portuguese). Methods and analysis: Individuals with PD are enrolled in the study in France (N=60) and Portugal (N=60). Their global motor disability and orofacial motor functions is assessed with specific clinical rating scales, without (OFF) and with (ON) pharmacological treatment. 2 groups of 60 healthy age-matched volunteers provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks are recorded to obtain acoustic and perceptual measures. Patient-reported outcome measures are used to assess the psychosocial impact of dysarthria on quality of life. Ethics and dissemination: The study has been approved by the local responsible committees on human experimentation and is conducted in accordance with the ethical standards. A valuable large-scale database of speech recordings and metadata from patients with PD in France and Portugal will be constructed. Results: will be disseminated in several articles in peer-reviewed journals and in conference presentations. Recommendations on how to assess speech and voice disorders in individuals with PD to monitor the progression and management of symptoms will be provided.

Original languageEnglish (US)
Article numbere012885
JournalBMJ open
Volume6
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Dysarthria
Parkinson Disease
Language
Portugal
Pharmacology
France
Human Experimentation
Communication
Voice Disorders
Speech Disorders
Aptitude
Acoustics
Ethics
Volunteers
Therapeutics
Quality of Life
Databases

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Keywords

  • Cross-language
  • Disease progression
  • Dysarthria
  • Parkinson's disease
  • Pharmacological treatment
  • Speech

Cite this

Pinto, Serge ; Cardoso, Rita ; Sadat, Jasmin ; Guimarães, Isabel ; Mercier, Céline ; Santos, Helena ; Atkinson-Clement, Cyril ; Carvalho, Joana ; Welby, Pauline ; Oliveira, Pedro ; D'Imperio, Mariapaola ; Frota, Sónia ; Letanneux, Alban ; Vigario, Marina ; Cruz, Marisa ; Martins, Isabel Pavão ; Viallet, François ; Ferreira, Joaquim J. / Dysarthria in individuals with Parkinson's disease : A protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark). In: BMJ open. 2016 ; Vol. 6, No. 11.
@article{2c8d950903154f97bc0daed7414a25fe,
title = "Dysarthria in individuals with Parkinson's disease: A protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark)",
abstract = "Introduction: Individuals with Parkinson's disease (PD) have to deal with several aspects of voice and speech decline and thus alteration of communication ability during the course of the disease. Among these communication impairments, 3 major challenges include: (1) dysarthria, consisting of orofacial motor dysfunction and dysprosody, which is linked to the neurodegenerative processes; (2) effects of the pharmacological treatment, which vary according to the disease stage; and (3) particular speech modifications that may be language-specific, that is, dependent on the language spoken by the patients. The main objective of the FraLusoPark project is to provide a thorough evaluation of changes in PD speech as a result of pharmacological treatment and disease duration in 2 different languages (French vs European Portuguese). Methods and analysis: Individuals with PD are enrolled in the study in France (N=60) and Portugal (N=60). Their global motor disability and orofacial motor functions is assessed with specific clinical rating scales, without (OFF) and with (ON) pharmacological treatment. 2 groups of 60 healthy age-matched volunteers provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks are recorded to obtain acoustic and perceptual measures. Patient-reported outcome measures are used to assess the psychosocial impact of dysarthria on quality of life. Ethics and dissemination: The study has been approved by the local responsible committees on human experimentation and is conducted in accordance with the ethical standards. A valuable large-scale database of speech recordings and metadata from patients with PD in France and Portugal will be constructed. Results: will be disseminated in several articles in peer-reviewed journals and in conference presentations. Recommendations on how to assess speech and voice disorders in individuals with PD to monitor the progression and management of symptoms will be provided.",
keywords = "Cross-language, Disease progression, Dysarthria, Parkinson's disease, Pharmacological treatment, Speech",
author = "Serge Pinto and Rita Cardoso and Jasmin Sadat and Isabel Guimar{\~a}es and C{\'e}line Mercier and Helena Santos and Cyril Atkinson-Clement and Joana Carvalho and Pauline Welby and Pedro Oliveira and Mariapaola D'Imperio and S{\'o}nia Frota and Alban Letanneux and Marina Vigario and Marisa Cruz and Martins, {Isabel Pav{\~a}o} and Fran{\cc}ois Viallet and Ferreira, {Joaquim J.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1136/bmjopen-2016-012885",
language = "English (US)",
volume = "6",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "11",

}

Pinto, S, Cardoso, R, Sadat, J, Guimarães, I, Mercier, C, Santos, H, Atkinson-Clement, C, Carvalho, J, Welby, P, Oliveira, P, D'Imperio, M, Frota, S, Letanneux, A, Vigario, M, Cruz, M, Martins, IP, Viallet, F & Ferreira, JJ 2016, 'Dysarthria in individuals with Parkinson's disease: A protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark)', BMJ open, vol. 6, no. 11, e012885. https://doi.org/10.1136/bmjopen-2016-012885

Dysarthria in individuals with Parkinson's disease : A protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark). / Pinto, Serge; Cardoso, Rita; Sadat, Jasmin; Guimarães, Isabel; Mercier, Céline; Santos, Helena; Atkinson-Clement, Cyril; Carvalho, Joana; Welby, Pauline; Oliveira, Pedro; D'Imperio, Mariapaola; Frota, Sónia; Letanneux, Alban; Vigario, Marina; Cruz, Marisa; Martins, Isabel Pavão; Viallet, François; Ferreira, Joaquim J.

In: BMJ open, Vol. 6, No. 11, e012885, 01.11.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dysarthria in individuals with Parkinson's disease

T2 - A protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark)

AU - Pinto, Serge

AU - Cardoso, Rita

AU - Sadat, Jasmin

AU - Guimarães, Isabel

AU - Mercier, Céline

AU - Santos, Helena

AU - Atkinson-Clement, Cyril

AU - Carvalho, Joana

AU - Welby, Pauline

AU - Oliveira, Pedro

AU - D'Imperio, Mariapaola

AU - Frota, Sónia

AU - Letanneux, Alban

AU - Vigario, Marina

AU - Cruz, Marisa

AU - Martins, Isabel Pavão

AU - Viallet, François

AU - Ferreira, Joaquim J.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Individuals with Parkinson's disease (PD) have to deal with several aspects of voice and speech decline and thus alteration of communication ability during the course of the disease. Among these communication impairments, 3 major challenges include: (1) dysarthria, consisting of orofacial motor dysfunction and dysprosody, which is linked to the neurodegenerative processes; (2) effects of the pharmacological treatment, which vary according to the disease stage; and (3) particular speech modifications that may be language-specific, that is, dependent on the language spoken by the patients. The main objective of the FraLusoPark project is to provide a thorough evaluation of changes in PD speech as a result of pharmacological treatment and disease duration in 2 different languages (French vs European Portuguese). Methods and analysis: Individuals with PD are enrolled in the study in France (N=60) and Portugal (N=60). Their global motor disability and orofacial motor functions is assessed with specific clinical rating scales, without (OFF) and with (ON) pharmacological treatment. 2 groups of 60 healthy age-matched volunteers provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks are recorded to obtain acoustic and perceptual measures. Patient-reported outcome measures are used to assess the psychosocial impact of dysarthria on quality of life. Ethics and dissemination: The study has been approved by the local responsible committees on human experimentation and is conducted in accordance with the ethical standards. A valuable large-scale database of speech recordings and metadata from patients with PD in France and Portugal will be constructed. Results: will be disseminated in several articles in peer-reviewed journals and in conference presentations. Recommendations on how to assess speech and voice disorders in individuals with PD to monitor the progression and management of symptoms will be provided.

AB - Introduction: Individuals with Parkinson's disease (PD) have to deal with several aspects of voice and speech decline and thus alteration of communication ability during the course of the disease. Among these communication impairments, 3 major challenges include: (1) dysarthria, consisting of orofacial motor dysfunction and dysprosody, which is linked to the neurodegenerative processes; (2) effects of the pharmacological treatment, which vary according to the disease stage; and (3) particular speech modifications that may be language-specific, that is, dependent on the language spoken by the patients. The main objective of the FraLusoPark project is to provide a thorough evaluation of changes in PD speech as a result of pharmacological treatment and disease duration in 2 different languages (French vs European Portuguese). Methods and analysis: Individuals with PD are enrolled in the study in France (N=60) and Portugal (N=60). Their global motor disability and orofacial motor functions is assessed with specific clinical rating scales, without (OFF) and with (ON) pharmacological treatment. 2 groups of 60 healthy age-matched volunteers provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks are recorded to obtain acoustic and perceptual measures. Patient-reported outcome measures are used to assess the psychosocial impact of dysarthria on quality of life. Ethics and dissemination: The study has been approved by the local responsible committees on human experimentation and is conducted in accordance with the ethical standards. A valuable large-scale database of speech recordings and metadata from patients with PD in France and Portugal will be constructed. Results: will be disseminated in several articles in peer-reviewed journals and in conference presentations. Recommendations on how to assess speech and voice disorders in individuals with PD to monitor the progression and management of symptoms will be provided.

KW - Cross-language

KW - Disease progression

KW - Dysarthria

KW - Parkinson's disease

KW - Pharmacological treatment

KW - Speech

UR - http://www.scopus.com/inward/record.url?scp=84996844579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996844579&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2016-012885

DO - 10.1136/bmjopen-2016-012885

M3 - Article

C2 - 27856480

AN - SCOPUS:84996844579

VL - 6

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 11

M1 - e012885

ER -